Company intelligence / Profile preview

BIOS Health

Cambridge, England, United Kingdom

Ownership: Private
Employees: ~40
Development stage: Other

Overview

BIOS Health has developed AI-powered neural interfaces and a Neural Dosing Platform designed to read, analyze, and “dose” the nervous system in real time. These technologies can identify disease-specific neural biomarkers and provide rapid feedback on therapeutic efficacy. The company is currently developing digital neural therapeutics and optimizing implantable devices for chronic disease and prosthetic interface applications. No Phase 2/3 trials or marketed products are reported as of October 2025

Therapeutic areas: ImmunologyCardiovascularEndocrinologyNeurologyOther
Modalities: Device (implantable neural interface)Digital therapy (neural digital therapeutics)AI-powered therapy
Industry: Digital Health Medical Devices

Partnerships

Seeking co-development and academic/venture partners

Beyond the preview

Go deeper on BIOS Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOS Health.

Explore the full profile